The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

IN BRIEF: Genedrive included in Public Health England framework

Mon, 19th Apr 2021 12:46

Genedrive PLC - Manchester-based molecular diagnostics firm - Wins Public Health England deal under Lot 1 of National Microbiology Framework. Lot 1 relates to supply of diagnostic goods and services. "The award of a framework contract is not exclusive to the company, nor a guarantee of orders, however it does allow participating authorities to issue call-off orders for products in the future," Genedrive says.

Current stock price: 73.36 pence, up 9.5% on Monday

Year-to-date change: up 51%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
24 May 2024 17:05

LONDON MARKET CLOSE: FTSE 100 stumbles as rain dampens retail sales

(Alliance News) - Stock prices in London closed mixed on Friday, with the FTSE 100 finishing lower, but smaller indices ending in the green.

24 May 2024 15:54

UK shareholder meetings calendar - next 7 days

24 May 2024 12:24

Genedrive test ordered by five Manchester area hospitals

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced on Friday that it has received initial orders for its Genedrive M...

24 May 2024 12:00

LONDON MARKET MIDDAY: FTSE 100 in red as UK election heats up

(Alliance News) - Stock prices in London were mostly in the red at midday Friday, as the UK election debate heats up and retail sales come in below ex...

24 May 2024 11:31

Genedrive announces orders for testing kit worth over GBP100,000

(Alliance News) - Genedrive PLC on Friday said it had received initial UK orders for its MT-RNR1 testing kit.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.